GYRE

Gyre Therapeutics Inc

• Seeking Alpha·17h ago

  Gyre Therapeutics GAAP EPS of -$0.04, revenue of $32.9M

• Dow Jones·1d ago

  Press Release: Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

• TipRanks·10/22 20:40

  Gyre Therapeutics Secures CEO and CFO with New Contracts

• TipRanks·10/05 15:40

  Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT), Actinium Pharmaceuticals (ATNM) and Gyre Therapeutics (GYRE)

• TipRanks·09/01 13:35

  Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

• TipRanks·08/26 13:28

  Gyre Therapeutics unveils capital-efficient global development strategy

• TipRanks·08/10 13:20

  Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)

• NASDAQ·08/10 07:37

  Gyre Q2 Loss Widens As Revenue Edges Lower; Reaffirms Revenue Guidance

• TipRanks·08/10 06:01

  Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

• TipRanks·08/07 15:35

  H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)

• NASDAQ·08/07 12:20

  Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

• Seeking Alpha·08/07 11:32

  Gyre Therapeutics GAAP EPS of -$0.12 misses by $0.06, revenue of $29.1M beats by $2.61M

• Dow Jones·08/07 11:11

  *Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE

• Dow Jones·08/07 11:10

  *Gyre Therapeutics 2Q Loss/Shr 12c >GYRE

• Dow Jones·08/07 11:10

  *Gyre Therapeutics 2Q Rev $29.1M >GYRE